Hematología

2023

1. A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

   Frontiers in Oncology, Vol. 13

2. AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib

   Cancer Reports, Vol. 6, Núm. 10

3. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

   HemaSphere, Vol. 7, Núm. 8, pp. E936

4. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program

   European Journal of Haematology, Vol. 111, Núm. 2, pp. 293-299

5. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

   Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

6. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

   Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

7. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

   Blood Cancer Journal, Vol. 13, Núm. 1

8. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

   Bone Marrow Transplantation

9. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia(Front. Oncol., (2022), 12, (968340), 10.3389/fonc.2022.968340)

   Frontiers in Oncology

10. Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry

    65th Annual Meeting of the American-Society-of-Hematology (ASH)

11. Expert opinion paper on the treatment of hemophilia a with emicizumab

    Hematology (Amsterdam, Netherlands), Vol. 28, Núm. 1, pp. 2166334

12. First description of bone marrow failure syndrome in Spain caused by mutations in the ERCC6L2 gene

    British Journal of Haematology

13. Galician Experience with Avatrombopag: Galician Thrombosis and Hemostasis Group

    Blood, Vol. 142, Núm. Supplement 1, pp. 5446-5446

14. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

    Journal of Thrombosis and Haemostasis

15. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations

    Microbiology spectrum, Vol. 11, Núm. 4, pp. e0067423

16. IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients

    Journal of Fungi, Vol. 9, Núm. 6

17. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

    British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871

18. Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

    Blood, Vol. 142, Núm. Supplement 1, pp. 4270-4270

19. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

20. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica